SAN DIEGO--(BUSINESS WIRE)--The Moores Cancer Center at the University of California, San Diego (UCSD) today announced that it has entered into a collaboration agreement with Medarex, Inc. relating to certain targets for antibody-based cancer therapeutics. A separate but related evaluation license agreement has been entered into between UCSD’s Office of Technology Transfer and Intellectual Property Services and Medarex for the associated intellectual property. Medarex is a biopharmaceutical company based in Princeton, N.J., with research facilities in Milpitas and Sunnyvale, CA.
